NICE (UK National Institute for Clinical Excellence) boosts capacity ahead of new, enlarged agenda
This article was originally published in Clinica
Executive Summary
The UK's Department of Health (DoH) has announced the technologies it will next submit to the National Institute for Clinical Excellence (NICE), subject to consultation with key stakeholders. Meanwhile, NICE has amended its appraisals process and is strengthening its capacity, ahead of a possible doubling of its workload.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.